| PRIMARY INFORMATION |
|---|
| ID | 1617 |
| PMID | 25173088 |
| Year | 2014 |
| Sequence | PHWSYLLR |
| Name | Leuprorelin |
| Length | 9 |
| N-Terminal Modification | Free |
| C-Terminal Modification | Free |
| Linear/ Cyclic | Linear |
| Chirality | L |
| Chemical Modification | None |
| Origin of Peptide | Synthetic |
| Nature of Peptide/Cargo | It is a potent luteinizing hormone-releasing hormone (LHRH) receptor agonist used invarious clinical applications, including the treatment of endometriosis,prostate cancer, central precocious puberty and in vitro fertilization regimens |
| Mechanism | Not mentioned |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Scanning electron microscopy. |
| Enhancer | None |
| Properties of enhancer | Not applicable |
| Concentration | 30 ml of 2 mg/ml leuprorelin acetate solution |
| Incubation time | 24 hours |
| Tissue permeability (value with units) | 0.5 mA/cm2 |
| Tissue Sample | Porcine ears' skin |
| Ex vivo/In vivo/In vitro | in vitro |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N1CCC[C@H]1C(=O)N[C@@H](Cc1nc[nH]c1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=[NH2])N)C=O |
